Sepsis - the challenges of science, politics and society

Start:

Thu, 10 Mar 2016, 10:30

End:

Fri, 11 Mar 2016, 05:10

Website:

http://www.cscc.uniklinikum-jena.de/en/leopoldina_symposium.html

Venue:

German National Academy of Sciences Leopoldina founded in 1652, the Leopoldina brings together some 1,500 outstanding scientists from about 30 countries. It is dedicated to the advancement of science for the benefit of humankind and to shaping a better future. In its role as the German National Academy of Sciences, the Leopoldina represents the German scientific community in international committees. It offers unbiased scientific opinions on political and societal questions, publishing independent studies of national and international significance. The Leopoldina promotes scientific and public debate, supports young scientists, confers awards for scientific achievements, conducts research projects, and campaigns for the human rights of persecuted scientists.

Exhibit

Symposia

Workshops

Organiser

Sponsor

Sepsis continues to cause millions of deaths worldwide of which at least two million fatalities could be avoided each year by preventive measures such as vaccination of at risk populations, better sanitation and clean care, as well as by early recognition and most basic elements of care. In addition, at least 2 million sepsis survivors per year suffer from significant long term complications of the syndrome. Currently, adequate treatment facilities for most of these patients are missing. Despite its high and increasing incidence sepsis is poorly recognized by health authorities, health care workers, policymakers, lay people and media. The implementation of effective measures for sepsis control and the development of improved infection and sepsis diagnostics, effective antimicrobials and sepsis specific therapies are urgently needed.

This Leopoldina Symposium brings together highly ranked policy makers, representatives of national and international health care authorities, most renowned clinical scientists, basic researchers, representatives of highly innovative diagnostic and pharmaceutic companies, media and communication experts and sepsis survivors to learn from each other about the most effective ways to:

Increase vaccination rates and adherence to hygienic standards
Improve preparedness in case of further pandemics
Increase awareness for sepsis among lay people and health care providers
Foster quality improvement projects in the hospital and outpatient setting
Implement antibiotic stewardship programs and stop the misuse of antimicrobials
Overcome the gap between resistance, novel and effective antimicrobials
Encourage the development of cost-effective diagnostics and sepsis-specific therapeutics
Develop and provide adequate treatment concepts for sepsis sequelae

Participation at the symposium is free of charge, but registration is required.

Please fill the form for ONLINE REGISTRATION

Program Thursday, 10 March 2016
Opening session
Chairs:
E. Rietschel, Berlin / P. Suter, Geneva
Start: 10:30
Welcome and introduction
W. Tiefensee, TMWWDG	G. Berg, Leopoldina
W. Rosenthal, FSU	K. Benndorf, UKJ
10:50 Keynote Lecture:
Role of poverty and environment for public health
A. Steiner, Executive Director of United Nations Environment Programme (UNEP) and Under-Secretary-General of the United Nations
11:20
The German strategy for infection and sepsis control
L. H. Wieler, RKI
11:40
The WHO approach to sepsis control
N. Shindo, WHO
12:00
Lessons to be learned from the Ebola epidemic
T. Stöbe, MSF
12:20
The burden of sepsis in children
N. Kissoon, Canada
12:40
The burden of sepsis - a call to action
K. Reinhart, Jena
13:00 Lunch Break
The challenges of science
Chairs:
M. Quintel, Göttingen / T. Hein, Dallas
14:00
Challenges in the development of novel diagnostics and therapeutics in sepsis
N. Riedemann, Jena
14:20
Challenges to preserve and develop effective antimicrobials
M. Pletz, Jena
14:40
Role and challenges of clinical sepsis research
S. Finfer, Australia
15:00
Lessons learned from cancer
M. Löffler, Leipzig
15:20
Lessons learned from cardiology
C. Schulze, Jena
15:40 Coffee Break
Novel approaches to sepsis control and health promotion
Chairs:
C. Spies, Berlin / R. Rossaint, Aachen
16:00
The Surviving Sepsis Campaign approach to guideline implementation
H. Gerlach, Berlin
16:20
The National Irish initiative to sepsis control
V. Hamilton, Ireland
16:40
The Scottish National Health Service approach to quality improvement
K. Rooney, Scotland
Novel approaches to sepsis control and health promotion II
Chairs:
K. Werdan, Halle / M. Weigand, Heidelberg
17:00
The NRC for Surveillance and Nosocomial infection’s approach
P. Gastmeier, Berlin
17:20
The Initiative for Quality in Medicine’s approach
A. Meier-Hellmann, Erfurt
17:40
The Center for Sepsis Control and Care’s approach
H. Rüddel, Jena
18:00
The perspective of a sepsis victim
A. Trumann, Heeslingen
Öffentlicher Abendvortrag
Moderation:
M. Bucher, Halle
19:00
Sepsis vermeiden und früh erkennen
F. M. Brunkhorst, Jena
Program Friday, 11 March 2016
Novel approaches to sepsis control and health promotion
Chairs:
B. Böttiger, Cologne / B. Löffler, Jena
08:30
The US approach to quality improvement for sepsis management
M. Levy, USA
08:50
The UK Sepsis Trust approach to awareness & quality improvement
R. Daniels, UK
09:10
Prepardness and the role of ICUs in the fight against pandemics
J. Marshall, Canada
09:30
The Turkish approach to improve sepsis awareness and sepsis management.
N. Unal, Turkey
09:50
The role of media during health crises
J. Müller-Jung, FAZ
10:10
New approaches to vaccination and health promotion
C. Betsch, Erfurt
10:30 Coffee break
Roadmap for development of innovative vaccines, diagnostics and therapeutics I
Chairs:
T. Koch, Dresden / L. Gattinoni, Milan
Role of private public partnership for development of innovative vaccines, diagnostics and therapeutics Lessons learned and expectations of:
Chairs:
M. Hecker, Greifswald / H. van Aken, Münster
15:30
A researcher and later entrepreneur
E. Ermantraut, Blink GmbH Jena
15:50
An international diagnostics corporate
V. Liebenberg, Thermo Fisher Scientific Hennigsdorf/Berlin
16:10
A global medical products manufacturer
M. Lugan, B. Braun Melsungen AG
16:30
A biotech company
J. Struck, AdrenoMed AG Hennigsdorf/Berlin
16:50
A university spin-off
N. Riedemann, inflaRx Jena
17:10 Closing remarks
M. Bauer, Jena